The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Pavlenko I.A.

GBU Rostovskoĭ oblasti "Patologoanatomicheskoe biuro", Rostov-na-Donu

Zavalishina L.É.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Povilaĭtite P.E.

GBU Rostovskoĭ oblasti "Patologoanatomicheskoe biuro", Rostov-na-Donu

gene amplification as a mechanism of clonal heterogeneity in breast cancer

Authors:

Pavlenko I.A., Zavalishina L.É., Povilaĭtite P.E.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2019;81(6): 49‑55

DOI: 10.17116/patol20198106149

Read: 9038 times

Download PDF (RU)
Contact the author
Table of contents

GENE AMPLIFICATION AS A MECHANISM OF CLONAL HETEROGENEITY IN BREAST CANCER
GENE AMPLIFICATION AS A MECHANISM OF CLONAL HETEROGENEITY IN BREAST CANCER

To cite this article:

Pavlenko IA, Zavalishina LÉ, Povilaĭtite PE. gene amplification as a mechanism of clonal heterogeneity in breast cancer. Russian Journal of Archive of Pathology. 2019;81(6):49‑55. (In Russ.)
https://doi.org/10.17116/patol20198106149

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The effect of acetylamide synthetic peptide HLDF-6 on cell differentiation in breast cancer. Russian Journal of Archive of Pathology. 2025;(2):5-10
Impact of tumor size on actuarial survival of patients with primary breast sarcoma: a case-control study. Piro­gov Russian Journal of Surgery. 2024;(12):38-43
Asse­ssment of risk factors for breast cancer deve­lopment in women living in the Sara­tov region. Russian Bulletin of Obstetrician-Gynecologist. 2024;(6):100-106
Left ventricular myocardial performance index (Tei index) as an early marker of cardiotoxicity in anti­tumor therapy. Russian Cardiology Bulletin. 2024;(4-2):137-143
Nottingham Prognostic Index rela­tion to cyto­kine-producing tumor mole­cular subtypes in breast cancer. Russian Journal of Preventive Medi­cine. 2025;(1):63-68
New pathogenic treatments for myasthenia gravis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):31-38
The possibilities of predicting and redu­cing the risk of breast cancer in women against the background of the use of assi­sted reproductive technologies. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):59-64
Neoadjuvant drug therapy and onco­logical outcomes in patients with stage I–II breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(1):5-12
Treatment outcomes of stage IIA–IIB breast cancer patients of hormone-positive HER2-negative subtype after neoadjuvant poly­chemotherapy depe­nding on Ki-67 levels. P.A. Herzen Journal of Onco­logy. 2025;(2):13-18
Clinical significance of gene­tic muta­tions in epithelial tumors of the thymus. P.A. Herzen Journal of Onco­logy. 2025;(2):70-75
Abstract:

Objective — to estimate the heterogeneity of HER2/neu gene amplification in HER2/neu-positive breast cancer (BC). Material and methods. Fluorescence in situ hybridization (FISH) assay was used to estimate HER2/neu gene amplification and HER2/CEP17 ratios in BC samples with an immunohistochemical evaluation of HER2/neu2+ expression. The results were interpreted according to the 2018 ASCO/CAP guidelines. BC samples with HER2/neu gene amplification (n = 25) was evaluated for variability in HER2/neu amplification and HER2/CEP17 ratios in 20 tumor cells counted using the FISH assay. Results. Significant intratumoral variability was found in the HER2/neu gene copy number and HER2/CEP17 ratios. HER2/neu-negative cells (5-15%) were present in 28% of the examined samples found to be HER2/neu positive. The HER2/neu gene copy number and HER2/CEP17 ratios for these tumors were statistically significantly lower than those in the group in which all the counted cells were characterized by HER2/neu amplification: 6.25 (95% CI 4.3—12.45; p=0.0166) and 2.37 (95% CI 2.06—3.43; p=0.0076), respectively. The threshold value of HER2/CEP17, at which cells without amplification were detected in HER2/neu-positive tumors, was 2.5. Conclusion. HER2/neu gene amplification in BC is extremely variable both within a single tumor and between the tumors of the same biological subtype. Amplification heterogeneity is statistically significantly more common in HER2/neu-positive BC with a HER2/CEP17 ratio <2.5 and may affect the outcome of the disease and also be important in the choice of treatment policy.

Keywords:

breast cancer
HER2 gene amplification heterogeneity
fluorescence in situ hybridization (FISH)
targeted therapy

Authors:

Pavlenko I.A.

GBU Rostovskoĭ oblasti "Patologoanatomicheskoe biuro", Rostov-na-Donu

Zavalishina L.É.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Povilaĭtite P.E.

GBU Rostovskoĭ oblasti "Patologoanatomicheskoe biuro", Rostov-na-Donu

Close metadata

References:

  1. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61-70.
  2. Frank GA, Andreeva YuYu, Danilova NV, Pozharisskiy KM, Zavalishina LE. Breast cancer. Practical guide for doctors. Eds. Frank GA, Pozharisskiy KM, Zavalishina LE. Moscow: Prakticheskaya meditsina, 2014. (In Russ.)
  3. Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer. Ann Rev Med. 2015;66:111-128. https://doi.org/10.1146/annurev-med-042513-015127
  4. Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M. HER2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. J Oncol Pract. 2018;4(7):437-441. https://doi.org/10.1200/JOP.18.00206
  5. Wolff AC, Hammond ME, Hicks DG, Dowsett M, Mcshane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997-4013. https://doi.org/10.1200/JCO.2013.50.9984
  6. Beca F, Polyak K. Intratumor heterogeneity in breast cancer. Adv Exp Med Biol. 2016;882:169-189. https://doi.org/10.1007/978-3-319-22909-6_7
  7. Ng CK, Martelotto LG, Gauthier A, Wen HC, Piscuoglio S, Lim RS, Cowell CF, Wilkerson PM, Wai P, Rodrigues DN, et al. Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biol. 2015;16:107. https://doi.org/10.1186/s13059-015-0657-6
  8. Buckley NE, Forde C, McArt DG, Boyle DP, Mullan PB, James JA, Maxwell P, McQuaid S, Salto-Tellez M. Quantification of HER2 heterogeneity in breast cancer-implications for identification of sub-dominant clones for personalised treatment. Sci Rep 2016;6:23383. https://doi.org/10.1038/srep23383
  9. Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med. 2017;4:227. https://doi.org/10.3389/fmed.2017.00227
  10. Ho J, Chan DBY, Lee S-C, Koay ESC. A study on the prevalence of HER2 genetic heterogeneity and its impact on breast cancer survival. J Clin Oncol. 2013;31(15, Suppl.):586. https://doi.org/10.1200/jco.2013.31.15_suppl.586
  11. Hou Y, Nitta H, Li Z. HER2 gene protein assay is useful to determine HER2 status and evaluate HER2 heterogeneity in HER2 equivocal breast cancer. Am J Clin Pathol. 2017;147(1):89-95. https://doi.org/10.1093/ajcp/aqw211
  12. Marotta M, Onodera T, Johnson J, Budd GT, Watanabe T, Cui X, Giuliano AE, Niida A, Tanaka H. Palindromic amplification of the ERBB2 oncogene in primary HER2-positive breast tumors. Sci Rep. 2017;7:41921. https://doi.org/10.1038/srep41921
  13. Pekar G, Kasselaki I, Pekar-Lukacs A, Dekany C, Hellberg D, Tot T. Equivocal (HER2 IHC 2+) breast carcinomas: gene‐protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits. Histopathology. 2019;74(2):300-310. https://doi.org/10.1111/his.13733
  14. Zavalishina LE, Danilova NV, Matsionis AE, Pavlenko IA. Specific features of gene amplification on the long arm of chromosome 17 in different molecular genetic subtypes of breast cancer. Arkhiv patologii. 2014;76(2):8-12. (In Russ.)
  15. Martelotto L, Ng CK, Piscuoglio S, Weigelt B, Reis-Filho JS. Breast cancer intra-tumor heterogeneity. Breast Cancer Res. 2014; 16(2):210. https://doi.org/10.1186/bcr3658
  16. Ellsworth RE, Blackburn HL, Shriver CD, Soon-Shiong P, Ellsworth DL. Molecular heterogeneity in breast cancer: state of the science and implications for patient care. Semin Cell Dev Biol. 2017;64:65-72. https://doi.org/10.1016/j.semcdb.2016.08.025
  17. McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613-628. https://doi.org/10.1016/j.cell.2017.01.018
  18. Seol H, Lee HJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Park SY. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. Mod Pathol. 2012;25(7):938-948.
  19. Lipinski KA, Barber LJ, Davies MN, Ashenden M, Sottoriva A, Gerlinger M. Cancer evolution and the limits of predictability in precision cancer medicine. Trends Cancer. 2016;2(1):49-63. https://doi.org/10.1016/j.trecan.2015.11.003
  20. Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, et al. In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer. Nat Genet. 2015;47(10):1212-1219. https://doi.org/10.1038/ng.339
  21. Rye IH, Trinh A, Saetersdal AB, Nebdal D, Lingjaerde OC, Almendro V, Polyak K, Børresen-Dale AL, Helland Å, Markowetz F, Russnes HG. Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors. Mol Oncol. 2018;12(11):1838-1855. https://doi.org/10.1002/1878-0261.12375
  22. Ballard M, Jalikis F, Krings G, Schmidt RA, Chen YY, Rendi MH, Dintzis SM, Jensen KC, West RB, Sibley RK, Troxell ML, Allison KH, et al. ‘Non-classical’ HER2 FISH results in breast cancer: a multi-institutional study. Mod Pathol. 2017;30(2):227-235. https://doi.org/10.1038/modpathol.2016.175
  23. Borley A, Mercer T, Morgan M, Dutton P, Barrett-Lee P, Brunelli M, Jasani B. Impact of HER2 copy number in IHC2+/FISH-amplified breast cancer on outcome of adjuvant trastuzumab treatment in a large UK cancer network. Br J Cancer. 2014;110(8):2139-2143. https://doi.org/10.1038/bjc.2014.147 Received 14.02.19
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.